Daiwa Securities Group Inc. Purchases 4,900 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Daiwa Securities Group Inc. grew its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 9.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,770 shares of the biotechnology company’s stock after purchasing an additional 4,900 shares during the period. Daiwa Securities Group Inc.’s holdings in Ironwood Pharmaceuticals were worth $364,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,645 shares during the period. CWM LLC lifted its stake in Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of Ironwood Pharmaceuticals by 68.8% during the fourth quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 3,497 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $91,000. Finally, GAMMA Investing LLC lifted its stake in shares of Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 8,156 shares during the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the sale, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 12.90% of the company’s stock.

Wall Street Analyst Weigh In

IRWD has been the subject of a number of recent analyst reports. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Wells Fargo & Company decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.57.

Ironwood Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ IRWD opened at $4.47 on Tuesday. The company has a 50 day simple moving average of $5.50 and a two-hundred day simple moving average of $6.73. Ironwood Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $15.70. The stock has a market cap of $714.04 million, a price-to-earnings ratio of -0.66 and a beta of 0.49.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.